Uso de la Passiflora incarnata como tratamiento complementario en la epilepsia idiopática canina

Frida Damara Romero-Rosales; Jailani Aitzel Segovia-Gómez; Carlos Rafael Lechuga de Blas; Juan Ocampo-López; Armando Zepeda Bastida; Samantha Macías-Robles

doi:10.29057/icap.v12i23.15416

Autores/as

Frida Damara Romero-Rosales Instituto de Ciencias Agropecuarias https://orcid.org/0009-0005-4722-7653
Jailani Aitzel Segovia-Gómez Instituto de Ciencias Agropecuarias https://orcid.org/0009-0003-2424-1474
Carlos Rafael Lechuga de Blas Instituto de Ciencias Agropecuarias https://orcid.org/0009-0003-6226-9494
Juan Ocampo-López Instituto de Ciencias Agropecuarias https://orcid.org/0000-0002-9208-7216
Armando Zepeda Bastida Área Académica de Medicina Veterinaria y Zootecnia https://orcid.org/0000-0003-0572-5206
Samantha Macías-Robles Universidad Autónoma del Estado de Hidalgo https://orcid.org/0009-0001-3983-7559

DOI:

https://doi.org/10.29057/icap.v12i23.15416

Palabras clave:

Epilepsia canina, GABA, Medicina complementaria, Planta

Resumen

La epilepsia idiopática es la causa más común de convulsiones en perros, se origina principalmente por un desbalance entre el ácido gamma aminobutírico y el glutamato; por lo regular son bien controladas cuando se tratan con anticonvulsivos, sin embargo, la mayoría de estos fármacos producen efectos secundarios en los pacientes. Un canino epiléptico presenta diversas comorbilidades, entre ellas la ansiedad y el estrés, por lo tanto, al momento de prescribir fármacos anticonvulsivos sería pertinente tener presente los factores internos y externos de cada paciente. Desde siempre se han empleado plantas y hierbas en el tratamiento de enfermedades en humanos y animales y la epilepsia no es una excepción, de hecho, la Passiflora incarnata puede ser una alternativa biotecnológica como tratamiento complementario, debido a que posee propiedades anticonvulsivas y ansiolíticas, sin embargo, los estudios científicos de esta planta aún no están suficientemente respaldados por evidencia clínica.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

[1] Chandler K. Canine epilepsy: what can we learn from human seizure disorders? 2005, 172(2), 207–217. https://doi.org/10.1016/j.tvjl.2005.07.001

[2] Goiz G, Caballero S, Solís H, Sumano H. Epilepsia en perros 2008, obtenido de http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0301-50922008000300005&lng=es&tlng=es.

[3] Patterson E. Epileptogenesis and companion animals. Topics in companion animal medicine 2013, 28(2), 42–45. https://doi.org/10.1053/j.tcam.2013.06.010

[4] Mariani L. Terminology and classification of seizures and epilepsy in veterinary patients. Topics in companion animal medicine 2013, 28(2), 34–41. https://doi.org/10.1053/j.tcam.2013.06.008

[5] Rosas A, Peña L. (2016). EPILEPSIA EN PERROS: REVISIÓN DE TEMA. Revista CITECSA 2016, obtenido de https://www.academia.edu/26166217/EPILEPSIA_EN_PERROS_REVISION_DE_TEMA

[6] Mathie R, Baitson E, Hansen L, Elliott M, Hoare J. Homeopathic prescribing for chronic conditions in feline and canine veterinary practice. Homeopathy : the journal of the Faculty of Homeopathy 2010, 99(4), 243–248. https://doi.org/10.1016/j.homp.2010.05.010

[7] Jawna, K., Blecharz, K., Joniec, I., Wawer, A., Pyrzanowska, J., Piechal, A., Mirowska, D., & Widy, E. (2016). Passiflora incarnata L. Improves Spatial Memory, Reduces Stress, and Affects Neurotransmission in Rats. Phytotherapy research : PTR, 30(5), 781–789. https://doi.org/10.1002/ptr.5578

[8] Aman U, Subhan F, Shahid M, Akbar S, Ahmad N, Ali G, Fawad K, Sewell R. Passiflora incarnata attenuation of neuropathic allodynia and vulvodynia apropos GABA-ergic and opioidergic antinociceptive and behavioural mechanisms. BMC complementary and alternative medicine 2016, 24:16:77. doi: 10.1186/s12906-016-1048-6.

[9] Mourenza L. Passiflora en el tratamiento de la ansiedad y el insomnio. Tesis de Facultad De Farmacia Universidad Complutense 2017, obtenido de https://docta.ucm.es/rest/api/core/bitstreams/df13e0f0-e489-42ac-8ebe-aea7236b3f9b/content

[10] Thomas W. Idiopathic Epilepsy in Dogs and Cats. Veterinary Clinics of North America: Small Animal Practice 2010, 40(1), 161–179. doi: 10.1016/j.cvsm.2009.09.004

[11] Uriarte A, Maestro Saiz I. Canine versus human epilepsy: are we up to date? Journal of Small Animal Practice 2016, 57(3), 115–121. doi:10.1111/jsap.12437

[12] Moore S. A clinical and diagnostic approach to the patient with seizures. Topics in companion animal medicine 2013, 28(2), 46–50. https://doi.org/10.1053/j.tcam.2013.07.002

[13] Blades S, Rossmeisl, J. Status epilepticus in dogs and cats, part 1: etiopathogenesis, epidemiology, and diagnosis 2017, 27(3), 278–287. https://doi.org/10.1111/vec.12605

[14] Pellegrino F. Clasificación de la epilepsia y síndromes epilépticos: una tarea pendiente para la medicina veterinaria 2014, obtenido de https://revistas.um.es/analesvet/article/view/283711

[15] Lavely J. Pediatric seizure disorders in dogs and cats 2014, 44(2), 275–301. https://doi.org/10.1016/j.cvsm.2013.10.004

[16] Charalambous M, Brodbelt D, Volk, H. Treatment in canine epilepsy – a systematic review 2014, obtenido de https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-014-0257-9

[17] Rundfeldt C. Quality of life of dogs with chronic epilepsy 2016, 178(26), 650–651. doi:10.1136/vr.i3444

[18] Suiter E, Packer R, Volk, H. Comparing the effects of first-line antiepileptic drugs on the gait of dogs with idiopathic epilepsy 2016, 178(26), 652–652. doi:10.1136/vr.103736

[19] Wessmann A, Volk HA, Packer R, Ortega M, Anderson T. Quality-of-life aspects in idiopathic epilepsy in dogs 2016, 179, 229. http://dx.doi.org/10.1136/vr.103355

[20] Meland T, Carrera S. Review: Emergency Management of Dogs With Suspected Epileptic Seizures 2021, 33(1), 17–20. https://doi.org/10.1053/j.tcam.2018.03.004

[21] Podell M. Antiepileptic drug therapy and monitoring 2013, 28(2), 59–66. https://doi.org/10.1053/j.tcam.2013.06.009

[22] Mínguez J. Epilepsia en Mínguez, J., Manual práctico de neurología veterinaria 2015, obtenido de https://issuu.com/editorialservet/docs/p28390_neurologia_dosier

[23] Camps T, Amat M, Manteca X. A Review of Medical Conditions and Behavioral Problems in Dogs and Cats 2019, 9(12), 1133. https://doi.org/10.3390/ani9121133

[24] LaFrance W, Kanner A, Hermann B. Psychiatric comorbidities in epilepsy 2008, 83, 347–383. https://doi.org/10.1016/S0074-7742(08)00020-2

[25] Beyenburg S, Mitchell, A, Schmidt D, Elger C, Reuber, M. Anxiety in patients with epilepsy: systematic review and suggestions for clinical management 2005, 7(2), 161–171. https://doi.org/10.1016/j.yebeh.2005.05.014

[26] Watson F, Packer R, Rusbridge C, Volk A. Behavioural changes in dogs with idiopathic epilepsy 2020, 186(3), 93. https://doi.org/10.1136/vr.105222

[27] Packer M, Volk A. Epilepsy beyond seizures: a review of the impact of epilepsy and its comorbidities on health-related quality of life in dogs 2015, 177(12), 306–315. https://doi.org/10.1136/vr.103360

[28] Boro A, Haut, S. Medical comorbidities in the treatment of epilepsy 2003, 4 Suppl 2, S2–S12. https://doi.org/10.1016/j.yebeh.2003.07.002

[29] Forsgård J, Metsähonkala L, Kiviranta A, Cizinauskas S, Junnila J, Laitinen-Vapaavuori O, Jokinen, T. Seizure-precipitating factors in dogs with idiopathic epilepsy. Journal of veterinary internal medicine 2019, 33(2), 701–707. https://doi.org/10.1111/jvim.15402

[30] Levitin H, Hague D, Ballantyne K, Selmic L. Behavioral Changes in Dogs With Idiopathic Epilepsy Compared to Other Medical Populations. Frontiers in veterinary science 2019, 8:6: 396. https://doi.org/10.3389/fvets.2019.00396

[31] Packer R, Hobbs S, Blackwell E. Behavioral Interventions as an Adjunctive Treatment for Canine Epilepsy: A Missing Part of the Epilepsy Management Toolkit? Frontiers in veterinary science 2019, 28:6: 3.doi: 10.3389/fvets.2019.00003.

[32] Spinella M. Herbal medicines and epilepsy: the potential for benefit and adverse effects 2001, 2(6):524-532. doi: 10.1006/ebeh.2001.0281.

[33] Laudato M, Capasso R. Useful plants for animal therapy 2013, obtenido de https://pdfs.semanticscholar.org/3bff/e9c536900d0b35899653a6877c1f09c5f333.pdf

[34] Lans C. Do recent research studies validate the medicinal plants used in British Columbia, Canada for pet diseases and wild animals taken into temporary care? 2019, 23:236:366-392. doi: 10.1016/j.jep.2019.02.030.

[35] Goel R, Gawande D, Lagunin A, Randhawa P, Mishra A, Poroikov. Revealing Medicinal Plants That Are Useful for the Comprehensive Management of Epilepsy and Associated Comorbidities through In Silico Mining of Their Phytochemical Diversity 2015, 81(6), 495–506. https://doi.org/10.1055/s-0035-1545884

[36] Sucher N,Carles, M. A pharmacological basis of herbal medicines for epilepsy 2015, 52(Pt B):308-18. doi: 10.1016/j.yebeh.2015.05.012.

[37] Saxena V, Nadkarni, V. Nonpharmacological treatment of epilepsy 2011, 14(3), 148–152. https://doi.org/10.4103/0972-2327.85870

[38] Miroddi M, Calapai G, Navarra M, Minciullo, P, Gangemi S. Passiflora incarnata L.: ethnopharmacology, clinical application, safety and evaluation of clinical trials 2013, 150(3), 791–804. https://doi.org/10.1016/j.jep.2013.09.047

[39] Schwartz S.Psychoactive Herbs in Veterinary Behavior Medicine 2005, obtenido de http://ndl.ethernet.edu.et/bitstream/123456789/3980/1/96.pdf.pdf

[40] Carlini E. Plants and the central nervous system. Pharmacology, biochemistry, and behavior 2003, 75(3), 501–512. https://doi.org/10.1016/s0091-3057(03)00112-6

[41] Raffaelli A, Moneti G, Mercati V, TojaE. Mass spectrometric characterization of flavonoids in extracts from Passiflora incarnata. Journal of Chromatography A 1997, 777(1), 223–231. doi:10.1016/s0021-9673(97)00260-4

[42] Wohlmuth H, Penman K, Pearson T,Lehmann, . Pharmacognosy and chemotypes of passionflower (Passiflora incarnata L.). Biological & pharmaceutical bulletin 2010, 33(6), 1015–1018. https://doi.org/10.1248/bpb.33.1015

[43] Dhawan K, Dhawan S, Sharma A. Passiflora: a review update. Journal of Ethnopharmacology 2004, 94(1), 1–23. doi:10.1016/j.jep.2004.02.023

[44] Khan H, Nabavi S. Passiflora (Passiflora incarnata). Nonvitamin and Nonmineral Nutritional Supplements 2019, 361–366. doi:10.1016/b978-0-12-812491-8.00049-7

[45] Diniz T, Silva, J, de Lima-Saraiva S, Ribeiro F, Pacheco A, de Freitas R, Quintans-Júnior, L, Quintans, J, Mendes R, Almeida J. The role of flavonoids on oxidative stress in epilepsy. Oxidative medicine and cellular longevity, 2015, 171756. https://doi.org/10.1155/2015/171756

[46] Jembrek M, Vlainic J. GABA Receptors: Pharmacological Potential and Pitfalls. Current pharmaceutical design 2015, 21(34), 4943–4959. https://doi.org/10.2174/1381612821666150914121624

[47] da Fonseca L, Rodrigues R, Ramos A, da Cruz J, Ferreira J, Silva J, Amaral A. Herbal Medicinal Products from Passiflora for Anxiety: An Unexploited Potential. TheScientificWorldJournal 2020, 6598434. https://doi.org/10.1155/2020/6598434

[48] Estrada R, Ubaldo D, Araujo A. Los flavonoides y el sistema nervioso central. Salud mental, obtenido de http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0185-33252012000500004&lng=es&tlng=es.

[49] Liu W, Ge T, Pan Z, Leng Y, Lv J, Li B. The effects of herbal medicine on epilepsy. Oncotarget 2017, 8(29), 48385–48397. https://doi.org/10.18632/oncotarget.16801

[50] Appel K, Rose T, Fiebich B, Kammler T, Hoffmann C, Weiss G. Modulation of the γ-aminobutyric acid (GABA) system by Passiflora incarnata L. Phytotherapy research : PTR 2011, 25(6), 838–843. https://doi.org/10.1002/ptr.3352

[51] Elsas S, Rossi, D, Raber, J, White G, Seeley C, Gregory W, Mohr C, Pfankuch T, Soumyanath A. Passiflora incarnata L. (Passionflower) extracts elicit GABA currents in hippocampal neurons in vitro, and show anxiogenic and anticonvulsant effects in vivo, varying with extraction method. Phytomedicine : international journal of phytotherapy and phytopharmacology 2010, 17(12), 940–949. https://doi.org/10.1016/j.phymed.2010.03.002

[52] Saroya A, Singh J. Neuropharmacology of Passiflora Genus. In Pharmacotherapeutic Potential of Natural Products in Neurological Disorders 2018, obtenido de https://link.springer.com/book/10.1007/978-981-13-0289-3

[53] Nassiri-Asl M, Shariati-Rad S, Zamansoltani F. Anticonvulsant effects of aerial parts of Passiflora incarnata extract in mice: involvement of benzodiazepine and opioid receptors. BMC complementary and alternative medicine 2007, 8:7:26. doi: 10.1186/1472-6882-7-26.

[54] Patel S, Verma N, Gauthaman K. Passiflora incarnata Linn: A review on morphology, phytochemistry and pharmacological aspects. Pharmacognosy Reviews 2009, obtenido de https://phcogrev.com/article/2009/3/5-19

[55] Wyn, S, Fougère B. Veterinary Herbal Medicine: A Systems-Based Approach. Veterinary Herbal Medicine 2009, 291–409. https://doi.org/10.1016/B978-0-323-02998-8.50024-X

[56] Kim M, Lim H, Lee H, Kim T. Role Identification of Passiflora Incarnata Linnaeus: A Mini Review. Journal of menopausal medicine 2017, 23(3), 156–159. https://doi.org/10.6118/jmm.2017.23.3.156

[57] Russo R, Autore G, Severino L. Pharmaco-Toxicological Aspects of Herbal Drugs Used in Domestic Animals. Natural Product Communications, 2009, 1934578X0900401. doi:10.1177/1934578x0900401230

[58] Tabach R, Rodrigues E. & Carlini E. Preclinical toxicological assessment of a phytotherapeutic product--CPV (based on dry extracts of Crataegus oxyacantha L., Passiflora incarnata L., and Valeriana officinalis L.). Phytother Res. 2009, 23(1):33-40. doi: 10.1002/ptr.2499. PMID: 19048610.

[59] Kim G, Yi S. Chronic oral administration of Passiflora incarnata extract has no abnormal effects on metabolic and behavioral parameters in mice, except to induce sleep. Laboratory animal research 2019, 30:35:31. doi: 10.1186/s42826-019-0034-9.